Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.68 SEK | +1.21% | +1.21% | +19.71% |
Sales 2023 | 57.6M 5.39M | Sales 2024 * | 96M 8.98M | Capitalization | 1.95B 183M |
---|---|---|---|---|---|
Net income 2023 | -327M -30.58M | Net income 2024 * | -291M -27.21M | EV / Sales 2023 | 25 x |
Net cash position 2023 | 195M 18.2M | Net Debt 2024 * | 103M 9.59M | EV / Sales 2024 * | 21.4 x |
P/E ratio 2023 |
-4.29
x | P/E ratio 2024 * |
-7.03
x | Employees | 29 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.61% |
Latest transcript on Egetis Therapeutics AB
1 day | +1.21% | ||
1 week | +1.21% | ||
Current month | +2.61% | ||
1 month | +1.21% | ||
3 months | +19.71% | ||
6 months | +49.94% | ||
Current year | +19.71% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 17-06-15 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 17-12-30 |
Chief Tech/Sci/R&D Officer | - | 22-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jacques Näsström
CTO | Chief Tech/Sci/R&D Officer | 65 | 10-06-23 |
Mats Blom
BRD | Director/Board Member | 59 | 21-03-31 |
Director/Board Member | 50 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 6.68 | +1.21% | 122,236 |
24-03-27 | 6.6 | +0.15% | 180,397 |
24-03-26 | 6.59 | -1.49% | 116,817 |
24-03-25 | 6.69 | -0.59% | 265,282 |
24-03-22 | 6.73 | +1.97% | 267,470 |
Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.71% | 182M | |
+33.46% | 701B | |
+26.24% | 571B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 319B | |
+0.74% | 210B | |
+2.95% | 210B | |
-6.05% | 201B | |
-3.61% | 157B |